Video of Investor Jim Mellon Presenting at Abundance 360 Summit 2019

Jim Mellon's Juvenescence venture is at present one of the few major venture organizations focused on approaches to treat aging as a medical condition. Mellon and his colleagues outlined their take on the field in a 2017 book, also called Juvenescence. We are fortunate in that he is among the first few high net worth individuals to both agree with the SENS philosophy of damage repair, and then, much more importantly, follow through in action as well as word. He is not just seeing a massive market opportunity in treating aging, though that is certainly there, but is doing this because he wishes to achieve the goal of radical life extension - far longer, healthier lives for all. Jim Mellon is a relentless promoter once he has entered a field. As the science progresses to clinical development, we need someone like this. He will pull in the largest, most conservative investment concerns who presently have next to no interest in treating aging, and his funds will enable the startups and development programs needed to produce therapies. This is the necessary next stage in the evolution of rejuvenation research and development: moving from the laboratory to the clinic, moving from startup with data to fully funded company with human trials underway. It is an enormous amount of work, and requires large amounts of funding. That funding doesn't just happen my magic; considerable effort goes into lining up all of the necessary moving parts. Jim Mellon - Abundance 360 Summi...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs

Related Links:

This study aimed to assess the relative safety and short-term efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (c-TACE) for treating peculiar anatomical sites of gastric cancer liver metastasis. MATERIAL AND METHODS Of the 68 patients with gastric cancer liver metastases confirmed by imaging and pathology, 35 were treated with DEB-TACE and 33 with c-TACE. The DEB-TACE group comprised 26 males and 9 females aged 28-75 years (56.8±6.3), and the c-TACE group included 19 males and 14 females aged 33-77 (60.2±9.4) years. Liver functions of th...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS The network pharmacology analysis reveals the molecular biological mechanism of Artemisia annua anti-NSCLC via multiple active components, multi-channels, and multi-targets. This suggests that Artemisia annua might be developed as a promising anti-NSCLC drug. PMID: 32474568 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
New J. Chem., 2020, Accepted Manuscript DOI: 10.1039/D0NJ01814G, PaperGurpreet Kaur, Monika Chaudhary, Kailash C Jena, Narinder Singh Abstract Environmental contamination due to increase in drug level is touching its alarming stage. There is an array of drugs such as antibiotics, antidepressants, analgesics, cancer chemotherapy drugs etc which... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Analyst, 2020, Advance Article DOI: 10.1039/D0AN00627K, PaperJun Liu, Cheng Cao We propose a novel GSH-generating prodrug to be used with a sulfonamide-induced “integrative” platform for selective cancer therapy. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Dr Fauci says he hasn ’t spoken to Trump in two weeks; New Zealand to consider easing restrictions earlier than planned; Mexico deaths pass 10,000. Follow the latest updatesSingapore reopens schoolsUK: Critics round on No 10 over ‘ridiculous’ rules for 14-day quarantineAustralia coronavirus updates – liveCoronavirus latest: at a glanceSee all our coronavirus coverage6.46amBSTTheAssociated Pressis carrying a report that says Chinese officials sat on releasing the genetic map, or genome, of the coronavirus for over a week after multiple government labs had fully decoded it, not sharing details key to ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news Infectious diseases Science Microbiology Medical research UK news US news Australia news Source Type: news
Emmie de Wit joins TWiV to explain her work on the pathogenesis of infection with SARS-CoV-2 in rhesus macaques, including studies on remdesivir and vaccine candidate. Hosts: Vincent Racaniello, Rich Condit, and Brianne Barker Guest: Emmie de Wit Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Respiratory disease in macaques inoculated with SARS-CoV-2 (Nature) Clinical benefit of remdesivir in SARS-CoV-2 infected macaques (bioRxiv) Remdesivir for MERS-CoV infection in macaques (PNAS) ChAdOX1 vaccination for SARS-CoV-2 in macaques ...
Source: This Week in Virology - MP3 Edition - Category: Virology Authors: Source Type: podcasts
BACKGROUND: The United States (US) and Canada are in the midst of an opioid overdose epidemic. Many people who use illicit drugs (PWUD) do not call an emergency number 911 at the scene of an overdose due to fear of arrest. In the US and Canada, when an ind...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Hi all, The CDC recommends the first immunization for live vaccines (s.a. MMR, Varicella) begin at 12 months of age. However, rotavirus is also a live vaccine but is administered at 2, 4, and 6 months, and is never administered after 8 months. I know that the rotavirus vaccine decreases the severity of illness if it is contracted and prevents most rotavirus cases in the US, but theoretically, why would this work before the immune system has matured enough?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Clinical Rotations Source Type: forums
Hi everyone! I’m looking for advice on which schools to apply to in this cycle. I qualify as Disadvantaged on AMCAS and have FAP so I am able to apply to 20 schools. I’ve left off the Philly schools for personal reasons but am open to any other suggestions for my school list. cGPA: 3.7, sGPA: 3.6 For additional context, I had a really rough first 3 semesters of undergrad which included loss of income for my family, a parent’s cancer diagnosis, and 2 hospitalizations for... WAMC/School List: 3.7 cGPA/3.6 sGPA/515 MCAT
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: What Are My Chances? WAMC Medical Source Type: forums
Publication date: Available online 31 May 2020Source: European Journal of RadiologyAuthor(s): Qi Zhang, Han Ouyang, Feng Ye, Shuang Chen, Lizhi Xie, Xinming Zhao, Xiaoduo Yu
Source: European Journal of Radiology - Category: Radiology Source Type: research
More News: Addiction | Age-Related Macular Degeneration (AMD) | Biology | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Cardiology | Chocolate | Conferences | Environmental Health | Fortamet | Funding | Fundraising | Gastroschisis Repair | Gene Therapy | Genetics | Germany Health | Headache | Heart | Heart Transplant | Hepatitis | Hepatitis C | Hepatitis Vaccine | Immunotherapy | Internet | Laboratory Medicine | Learning | Liver | Liver Transplant | Men | Metformin | Migraine | Orthopaedics | Osteoarthritis | Osteoporosis | Pfizer | Science | Sports Medicine | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | Veterinary Vaccinations | Women